New drug aims to tame dangerous heart rhythms in genetic disorder
NCT ID NCT07277582
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug THRV-1268 can safely shorten the heart's electrical recovery time (QT interval) in people with Long QT Syndrome Type 2, a genetic condition that raises the risk of dangerous heart rhythms and sudden cardiac arrest. About 64 participants will take the drug twice daily at different doses for 6 weeks, with heart monitoring and clinic visits. The goal is to find a dose that works best and is safe, with the possibility of continuing treatment for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THRV-1268
What this could lead to
If it works, this could provide a new treatment option to control heart rhythm and reduce the risk of dangerous events in people with Long QT Syndrome Type 2.
What could go wrong
This is an early-to-mid-stage trial with only 64 participants, so results may not apply to everyone. The drug may cause side effects or fail to shorten the QT interval effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG QT SYNDROME (LQTS) 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heart Center Clinical Research Program | MGH
RECRUITINGBoston, Massachusetts, 02114, United States
-
Honor Health Research and Innovation Institute
RECRUITINGScottsdale, Arizona, 85258, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Illinois Chicago
RECRUITINGChicago, Illinois, 60612, United States
-
Wilmington Health
RECRUITINGWilmington, North Carolina, 28401, United States